Post-market surveillance reports show hepatic decompensation and hepatic failure associated with Viekira Pak use. It is likely that most patients who experienced this had advanced cirrhosis prior to treatment initiation. Hepatic decompensation is described by rising bilirubin without ALT elevations alongside clinical symptoms such as ascites and hepatic encephalopathy. Patients should be monitored for signs of hepatic decompensation and bilirubin levels should be tested in the first four weeks of treatment and compared to baseline.<unk>  could cause hepatitis B re-activation in people co-infected with hepatitis B and C viruses. The European Medicines Agency recommended screening all people for hepatitis B before starting<unk>  for hepatitis C in order to minimize the risk of hepatitis B reactivation.
Ombitasvir/paritaprevir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Sofosbuvir/velpatasvir/voxilaprevir
Glecaprevir/pibrentasvir
Abacavir/lamivudine
Sofosbuvir/velpatasvir
Abacavir/lamivudine/zidovudine